Dynamis Pharmaceuticals $539000 Financing. Devon Pope Filed Jun 13 Form D

June 13, 2018 - By Julie Dion

Dynamis Pharmaceuticals Financing

Dynamis Pharmaceuticals, Inc., Corporation just had published form D for $539,000 equity and debt financing. The date of first sale was 2017-06-14. Dynamis Pharmaceuticals was able to finance itself with $539,000. That is 100.00 % of the fundraising. The total financing amount was $539,000. The offering form was filed on 2018-06-13. The reason for the financing was: unspecified.

The firm’s business is Pharmaceuticals. The SEC form was submitted by Devon Pope Attorney. The company was incorporated more than five years ago. The filler’s address is: 261 Old York Road, Suite 427, Jenkintown, Pa, Pennsylvania, 19046. Annette Tobia is the related person in the form and it has address: 261 Old York Road, Suite 427, Jenkintown, Pa, Pennsylvania, 19046. Link to Dynamis Pharmaceuticals Filing: 000170860618000003.

Analysis of Dynamis Pharmaceuticals Offering

On average, companies in the Pharmaceuticals sector, sell 60.90 % of the total offering amount. Dynamis Pharmaceuticals sold 100.00 % of the offering. Could this mean that the trust in Dynamis Pharmaceuticals is high? The average offering amount for companies in the Pharmaceuticals industry is $556,000. The offering was 3.06 % smaller than the average of $556,000. Of course this should not be interpreted as negative. Businesses raise funds for different needs and reasons. The minimum investment for this fundraising was set at $3000. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Dynamis Pharmaceuticals Also

The Form D signed by Devon Pope might help Dynamis Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: